TISSIUM Raises €60 Million to Expand Commercial Operations and Clinical Programs

The funding comes after several major milestones for the company. TISSIUM received FDA approval for COAPTIUM® CONNECT, its first commercial product, launched the product in the U.S. market, and continued developing new treatments for nerve repair, hernia repair, and cardiovascular conditions.

Read Also- LiveKid Acquires Aldea to Strengthen Presence Across Latin America

The €30 million Series D2 funding round was completed at the end of 2025 with support from both new and existing investors, including several investors from the United States. This investment further strengthens TISSIUM’s investor base and supports the company's long-term growth plans.

The funds will be used to expand TISSIUM’s commercial operations, advance its clinical programs, develop new products, and continue growing its biomorphic polymer technology platform.

In addition, TISSIUM secured up to €30 million from the European Investment Bank. The funding will be released in three €10 million installments based on the company achieving specific commercial, clinical, and financing milestones. TISSIUM expects to receive the first €10 million tranche before the end of June 2026.

The combined funding gives TISSIUM greater flexibility to expand the U.S. rollout of COAPTIUM® CONNECT, advance multiple clinical programs, and continue developing its proprietary biomorphic polymer technology for tissue reconstruction and surgical applications.

Christophe Bancel, CEO and co-founder, TISSIUM, said: “This financing marks an important milestone in TISSIUM’s evolution. Following the FDA marketing authorization of COAPTIUM® CONNECT, we are now executing on our transition into a commercial-stage MedTech company while continuing to advance a differentiated pipeline built on the same underlying biomorphic polymer platform. The support of both leading international investors and the European Investment Bank reflects confidence in our technology, our strategy and our ability to bring meaningful innovation to patients. This financing provides the capital and strategic flexibility required to accelerate commercial execution while continuing to invest in the future growth of our platform.”